. 2022 Mar 14;10(3):611. doi: 10.3390/microorganisms10030611

Table 3.

Epidemiology of pAmpC-BLs in America (2010–2020).

Author (Reference)	Year of Population Study	Year of Publication	Country of Target Population	Population (H/C) ^a	Specific Conditions	n	AmpC (%) ^b		Global ^c	Genetic Identification	Most Frequent AmpC Enzymes
Author (Reference)	Year of Population Study	Year of Publication	Country of Target Population	Population (H/C) ^a	Specific Conditions	n	E. coli	K.pneumoniae	Global ^c	Genetic Identification	Most Frequent AmpC Enzymes
Park et al. [53]	2008–2012	2012	USA	H	3GCR	300	16.33	-	-	PCR/WGS	CMY-2
Suwantarat et al. [32]	2014–2015	2016	USA	H	EI	854	-	-	1.30	PCR/WGS	CMY-2
Logan et al. [55]	2011–2015	2016	USA	H	MDR	225	14.22	-	-	PCR/WGS	CMY-2
Paniagua-Contreras et al. [54]	Data not available	2018	Mexico	C	ECI	194	23.70	-	-	PCR	CIT group
Tamma et al. [52]	2014–2015	2019	USA	H	EI	1,929	2.23	0.88	3.42	PCR	CMY-2

^a Type of population studied: Hospital (H)/Community (C). ^b Percentage of positivity for AmpC among all isolates evaluated in the study. ^c Percentage global positivity that includes species other than E. coli and K. pneumoniae and/or does not differentiate between cAmpC-BL and pAmpC-BL. PCR: polymerase chain reaction; WGS: whole genome sequencing; ECI: E. coli isolates; 3GCR: third-generation cephalosporin-resistant; EI: Enterobacteriaceae isolates; MDR: multidrug resistant.